➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Johnson and Johnson
Express Scripts
Merck

Last Updated: May 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AZD8871

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD8871?

AZD8871 is an investigational drug.

There have been 5 clinical trials for AZD8871. The most recent clinical trial was a Phase 1 trial, which was initiated on October 10th 2018.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are AstraZeneca, Parexel, and Industrias Farmacéuticas Almirall S.A.

There are four US patents protecting this investigational drug and eighty-five international patents.

Recent Clinical Trials for AZD8871
TitleSponsorPhase
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.ParexelPhase 2
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.AstraZenecaPhase 2
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese SubjectsCovancePhase 1

See all AZD8871 clinical trials

Clinical Trial Summary for AZD8871

Top disease conditions for AZD8871
Top clinical trial sponsors for AZD8871

See all AZD8871 clinical trials

US Patents for AZD8871

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD8871   Get Started Free Combinations comprising MABA compounds and corticosteroids Almirall, S.A. (Barcelona, ES)   Get Started Free
AZD8871   Get Started Free Cyclohexylamine derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activities ALMIRALL, S.A. (Barcelona, ES)   Get Started Free
AZD8871   Get Started Free Cyclohexylamine derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activities Almirall, S.A. (Barcelona, ES)   Get Started Free
AZD8871   Get Started Free Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activities Almirall, S.A. (Barcelona, ES)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD8871

Drugname Country Document Number Estimated Expiration Related US Patent
AZD8871 Argentina AR097078 2033-07-25   Get Started Free
AZD8871 China CN105407890 2033-07-25   Get Started Free
AZD8871 European Patent Office EP3024459 2033-07-25   Get Started Free
AZD8871 Spain ES2727526 2033-07-25   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
AstraZeneca
Moodys
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.